Related Experiment Video
Updated: Jul 3, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced
Sijia Zhang1, Leichong Chen1, Kuikui Zhu1
1Cancer Center, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
In recent years, with the opening of the era of precision therapy, the treatment of patients with positive driver genes is a hot issue in global research. EGFR is the most common driver gene in NSCLC, with a positivity rate of 17%. Although targeted drugs for EGFR mutations can benefit this population with efficacy, target therapy resistance inevitably occurs. The presented case suggests that a patient with advanced lung adenocarcinoma with EGFR mutation who developed pathological-type conversion of small cell lung cancer complicated with the development of hypertropic pulmonary osteoarthropathy (HPOA) after 6 months of targeted therapy. This case demonstrates that early diagnosis of HPOA can predict the occurrence of target resistance and pathologic conversion in patients with positive driver genes, providing new clues for the clinical management of lung cancer.
Insights
Precision therapy for EGFR-mutated lung cancer faces resistance. Early diagnosis of hypertrophic pulmonary osteoarthropathy (HPOA) may predict target resistance and pathological conversion in lung adenocarcinoma.
Area of Science:
- Oncology
- Precision Medicine
- Pulmonology
Background:
- Epidermal Growth Factor Receptor (EGFR) mutations are common in non-small cell lung cancer (NSCLC), driving targeted therapy use.
- Targeted therapies offer benefits but inevitably lead to treatment resistance.
Observation:
- A patient with advanced EGFR-mutated lung adenocarcinoma developed small cell lung cancer and hypertrophic pulmonary osteoarthropathy (HPOA).
- This transformation occurred six months after initiating targeted therapy.
Findings:
- Hypertropic pulmonary osteoarthropathy (HPOA) development can signal impending target resistance.
- HPOA may also predict pathological-type conversion in driver gene-positive lung cancer.
Implications:
- Early HPOA diagnosis could offer predictive value for treatment resistance and histologic transformation in NSCLC.
- This finding provides new insights for managing lung cancer patients undergoing targeted therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
